Mi az ára EFFECTOR Therapeutics, Inc. (EFTRW)

EFFECTOR Therapeutics, Inc. (EFTRW) ára $0.0006

Mi a EFFECTOR Therapeutics, Inc. (EFTRW piaci tőkésítése)

EFFECTOR Therapeutics, Inc. piaci tőkésítése (EFTRW) $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) Ár és Piaci Kapitalizáció

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

A EFTRW ára	B aktíva	A B piaci tőkésítése	Eredmények
$1,144,584 $2.82K	NVDA	$5.383T	+190,763,991,449.54%
$940,480 $2.82K	AAPL	$4.423T	+156,746,687,257.60%
$884,558 $2.82K	GOOG	$4.160T	+147,426,282,463.24%
$778,878 $2.82K	MSFT	$3.663T	+129,812,937,413.32%
$614,719 $2.82K	AMZN	$2.891T	+102,453,189,138.36%

A EFTRW ára

B aktíva

A B piaci tőkésítése

Eredmények

$1,144,584 $2.82K